• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update

    10/14/21 5:23:09 PM ET
    $CMLF
    Business Services
    Finance
    Get the next $CMLF alert in real time by email
    smfr-20211008
    0001818331false00018183312021-10-082021-10-080001818331us-gaap:CommonClassAMember2021-10-082021-10-08


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): October 14, 2021 (October 8, 2021)


    Sema4 Holdings Corp.
    (Exact name of registrant as specified in its charter)
    Delaware
    001-39482
    85-1966622
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (I.R.S. Employer Identification No.)
    333 Ludlow Street, North Tower, 8th Floor
    06902
    Stamford,Connecticut
    (Address of Principal Executive Offices)
    (Zip Code)
    (800) 298-6470
    Registrant's telephone number, including area code
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Class A common stock, par value $0.0001 per shareSMFRThe Nasdaq Global Select Market
    Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per shareSMFRWThe Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




    Item 5.02           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Sema4 Holdings Corp. (“Sema4 Holdings” or the “Company”) has received confirmation that James Coffin, Ph.D. the Company’s Treasurer from January 2021 to March 2021, and President and Chief Operating Officer since 2017, expects to be on short-term disability leave for medical reasons for approximately 90 days, commencing sometime in October 2021 (the “Leave”).

    During the Leave, the Company’s Chief Financial Officer, Isaac Ro, and Chief Business Officer, Kareem Saad, will each perform functions previously performed by Dr. Coffin. 

    The Company does not anticipate that the Leave will adversely impact the Company’s financial performance and timelines for its corporate objectives, research and development progress, or strategic partnerships and collaborations.

    Except for historical information, this report contains certain forward-looking statements that involve known and unknown risk and uncertainties. These forward-looking statements relate to the Company’s expectations regarding the Leave. These risks and uncertainties are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, Dr. Coffin’s medical condition, and other risks and uncertainties identified in Sema4 Holdings Corp.’s filings with the Securities and Exchange Commission.





































    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Sema4 Holdings Corp.
          Date: October 14, 2021By:/s/ Eric Schadt
    Name:Eric Schadt
    Title:Chief Executive Officer

    Get the next $CMLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMLF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLF
    Financials

    Live finance-specific insights

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology

    $CMLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      10/13/21 2:31:34 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/30/21 4:45:58 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/2/21 4:59:57 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

      6/17/21 7:00:00 AM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

      Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

      7/22/21 9:15:41 AM ET
      $TWST
      $MGTA
      $CMLF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Business Services
    • Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA

      7/7/21 7:00:00 AM ET
      $TWST
      $CMLF
      $MGTA
      $OMIC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Finance

    $CMLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sherman Rachel E.

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:31:01 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Turner Nat

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:29:25 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Pellini Michael J

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:27:37 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    SEC Filings

    See more
    • SEC Form 424B3 filed by CM Life Sciences, Inc.

      424B3 - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 9:58:15 PM ET
      $CMLF
      Business Services
      Finance
    • CM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update

      8-K - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 5:23:09 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form S-8 filed by CM Life Sciences, Inc.

      S-8 - Sema4 Holdings Corp. (0001818331) (Filer)

      9/27/21 4:46:23 PM ET
      $CMLF
      Business Services
      Finance